Docket Number 3236

Received: 
Friday, July 7, 2017
Commodity: 
Recombinant Factor IX Products
Investigation Number: 
337-TA-1066
Filed By: 
David F. Nickel
Firm/Organization: 
Foster, Murphy, Altman, & Nickel
Behalf Of: 
Bioverativ Inc., Bioverativ Therapeutics Inc., and Bioverativ U.S. LLC
Confidential: 
Yes
Country: 
None
Description: 
Letter to Lisa R. Barton, Secretary, USITC; requesting that the Commission conduct an investigation under section 337 of the Tariff Act of 1930, as amended, regarding Certain Recombinant Factor IX Products. The proposed respondents are CSL Behring LLC, King of Prussia, Pennsylvania; CSL Behring GmbH, Germany; and CSL Behring Recombinant Facility AG, Switzerland.
Status Dropdown: 
Instituted